Intelligence

Healthcare

Cardiol Therapeutics Concludes Patient Enrollment in Phase II Study for CardiolRx™

Author:
FAQsIR News Desk
Last Updated:
Reading Time
3 min

#Overview of the MAvERIC-Pilot Study

Cardiol Therapeutics Inc. has announced that it has completed patient enrollment in its Phase II open-label pilot study, known as MAvERIC-Pilot. This study is focused on evaluating the safety, tolerability, and efficacy of CardiolRx™, a therapeutic agent aimed at patients suffering from recurrent pericarditis.

#Future Expectations

Topline results from the MAvERIC-Pilot study are anticipated to be reported in the second quarter of 2024. These findings are expected to be crucial in shaping the design of a subsequent pivotal Phase III clinical trial, which is necessary to support potential regulatory approval of CardiolRx™.

#The Clinical Challenge of Recurrent Pericarditis

Recurrent pericarditis is characterized by inflammation of the pericardium, the membrane surrounding the heart, which often follows an initial episode. Symptoms can lead to significant discomfort and productivity losses, including debilitating chest pain and fatigue. Current treatment options are limited, with only one FDA-approved therapy available, which is generally used as a third-line intervention due to its high cost.

#Study Participation and Goals

The MAvERIC-Pilot study enrolled a targeted cohort of 25 patients in the United States. Data collected will not only focus on safety assessments but will also evaluate tangible improvements in patient-reported outcomes over specified timeframes. Key endpoints include changes in pain perception and levels of inflammatory markers.

#Regulatory and Development Significance

CardiolRx™ has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), which may expedite its development process and enhance its market potential. This designation showcases the promising role CardiolRx™ could play in treating recurrent pericarditis, a condition that affects an estimated 38,000 patients annually in the United States.

#Key Takeaways

  • Cardiol Therapeutics has completed enrollment in the MAvERIC-Pilot Phase II study for CardiolRx™.
  • Topline results are expected in Q2 2024, which will inform future Phase III trial designs.
  • Recurrent pericarditis is a significant health issue, with few effective treatment options currently available.
  • CardiolRx™ has received Orphan Drug Designation from the FDA, indicating its potential significance in treating rare diseases.

#What is the MAvERIC-Pilot study, and what is it investigating?

The MAvERIC-Pilot study is a Phase II open-label pilot study designed to investigate the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis.

#When are topline results from the MAvERIC-Pilot study expected to be released?

Topline results from the MAvERIC-Pilot study are anticipated in Q2 2024.

#What is CardiolRx™, and how is it being developed?

CardiolRx™ is an oral cannabidiol solution developed by Cardiol Therapeutics for treating heart diseases, particularly recurrent pericarditis.

#How many patients were enrolled in the MAvERIC-Pilot study?

The MAvERIC-Pilot study has successfully enrolled its target of 25 patients in the United States.

#What are the primary and secondary endpoints of the MAvERIC-Pilot study?

The primary efficacy endpoint focuses on the change in patient-reported pericarditis pain using an 11-point numeric rating scale at 8 weeks.

#What are the clinical implications of recurrent pericarditis?

Recurrent pericarditis is associated with significant symptoms that negatively impact patients' quality of life and may lead to hospitalization.

#What is the significance of receiving Orphan Drug Designation for CardiolRx™?

Receiving Orphan Drug Designation from the FDA can facilitate faster development and provide financial incentives for the company.

#What future plans does Cardiol Therapeutics have for CardiolRx™?

Cardiol Therapeutics plans to use findings from the MAvERIC-Pilot study to design a pivotal Phase III trial aimed at seeking regulatory approval for CardiolRx™.

Original source: Read original article

Frequently Asked Questions

The MAvERIC-Pilot study is a Phase II open-label pilot study designed to investigate the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis. Completion of patient enrollment is a significant milestone that indicates progress in exploring promising therapeutic options for this debilitating condition.
Topline results from the MAvERIC-Pilot study are anticipated in Q2 2024. These upcoming results could provide critical insights that may guide future pivotal Phase III clinical trials, potentially advancing the regulatory approval process for CardiolRx™.
CardiolRx™ is an oral cannabidiol solution developed by Cardiol Therapeutics for treating heart diseases, particularly recurrent pericarditis. The drug has shown promise in early studies and has received Orphan Drug Designation from the FDA, highlighting its potential significance in addressing unmet medical needs in this area.
The MAvERIC-Pilot study has successfully enrolled its target of 25 patients in the United States. This completion of enrollment underscores the interest in and need for effective treatments for recurrent pericarditis, positioning Cardiol Therapeutics for potential advancements in patient care.
The primary efficacy endpoint focuses on the change in patient-reported pericarditis pain using an 11-point numeric rating scale at 8 weeks. Secondary endpoints include longer-term pain assessments and changes in inflammatory markers. Establishing efficacy through these endpoints could bolster the case for CardiolRx™ as a viable treatment option.
Recurrent pericarditis is associated with significant symptoms that negatively impact patients' quality of life and may lead to hospitalisation. As the only FDA-approved therapy is primarily a costly third-line option, effective new therapies like CardiolRx™ could offer substantial relief and improve patient outcomes in this underserved market.
Receiving Orphan Drug Designation from the FDA is a notable achievement for CardiolRx™, as it can facilitate faster development and provide financial incentives for the company. This designation reflects the drug’s potential importance in treating a rare disease, which may enhance investor interest and confidence in Cardiol Therapeutics.
Following the anticipated results from the MAvERIC-Pilot study, Cardiol Therapeutics plans to inform the design of a pivotal Phase III trial for CardiolRx™, aiming for regulatory approval. This next phase of development is crucial for bringing much-needed therapies to patients struggling with recurrent pericarditis.